AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02285790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision
Description: Excision of the suspected basal cell carcinoma lesion under local anesthetics
Study NCT02285790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical excision
Description: Excision of the suspected basal cell carcinoma lesion under local anesthetics
Study NCT01366209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
Study NCT01366209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent given as 3 divided doses 3 times per day.
Study NCT01655706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
Study NCT01655706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
Study NCT02225847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gardening
Description: The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
Study NCT02475343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA/riboflavin
Description: The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
Study NCT02225847 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
Study NCT02225847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
Study NCT02225847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychometric assessments
Description: The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
Study NCT05311540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Study NCT02225847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychometric assessments
Description: The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
Study NCT01753791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg PF-06473871
Description: 80 mg of PF-06473871 or placebo
Study NCT01753791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg PF-06473871
Description: 160 mg of PF-06473871 or placebo
Study NCT01753791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320 mg PF-06473871
Description: 320 mg of PF-06473871 or placebo
Study NCT01753791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg PF-06473871
Description: 480 mg of PF-06473871 or placebo
Study NCT05510804 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ALISA
Description: assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
Study NCT05510804 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ALISA
Description: assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
Study NCT02475343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femto-LASIK
Description: The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
Study NCT02475343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomey SP-100 Pchymeter , Topolyzer Vario
Description: Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
Study NCT02475343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topcon CT-80, Topcon, Japan
Description: Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
Study NCT02475343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corvis-ST
Description: Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
Study NCT01492049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRCS patient decision aid (PtDA) video
Description: Participant views PtDA program video in same room as research assistant who offers instruction as needed.
Study NCT01492049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
Study NCT01492049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
Study NCT01492049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Essential Hypertension video
Description: Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
Study NCT03961451 — intervention group
Intervention type: DEVICE
Intervention: Podometer
Description: Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
Study NCT03301870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201 Gel 2%
Description: 2% active gel
Study NCT02460614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinopharyngeal clearance
Description: At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
Study NCT02460614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration
Description: A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
Study NCT02460614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline consists of physiological solution and was instilled in both experimental groups.
Study NCT02460614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Description: 0.9% saline consists of physiological solution and was instilled in both experimental groups.
Study NCT04666389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
Study NCT04666389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
Study NCT01324505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
Study NCT01324505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
Study NCT01324505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgyn®
Description: Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
Study NCT01624389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-AV45
Description: This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Study NCT01612936 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage
Description: On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent.
Study NCT01612936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Description: Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
Study NCT03658655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells From Human Exfoliated Teeth
Description: Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline.
Study NCT04419584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Qing-Ying Decoction
Description: Herbal granules
Study NCT04419584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical looking placebo
Description: Placebo granules
Study NCT02648178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO
Description: HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
Study NCT01414283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: PSMA ADC administered IV
Study NCT04873791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of geriatric individuals living in home environment and nursing home.
Description: Assessments explained in the arm section were made as described in one session in both group
Study NCT05149651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Totalfill
Description: Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
Study NCT05149651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
Study NCT03135158 — intervention group
Intervention type: OTHER
Intervention: Exposure to vaginal delivery
Description: Women who have vaginal births are observed for a minimum of 1 hour postpartum
Study NCT01841125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: escitalopram 15mg, QD(once a day), Oral medication, 24weeks
Study NCT01841125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 15mg, QD(once a day), Oral medication
Study NCT01745744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells from adipose tissue
Description: - Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
Study NCT01726400 — intervention group
Intervention type: DRUG
Intervention: Pegylated interferon alpha
Description: Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
Study NCT01726400 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
Study NCT03494530 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 60 MG
Description: Anticoagulant used to treat atrial fibrillation
Study NCT03494530 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban 30 mg
Description: Anticoagulant used to treat atrial fibrillation
Study NCT00178919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
Study NCT00178919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
Study NCT00823433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral penicillin V
Description: 2 grams of oral penicillin V given within 4 hours of delivery.
Study NCT03541967 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ADHEAR and PONTO 3 SUPER POWER on softband hearing aids
Description: Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
Study NCT03267719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Transvaginal erbium-laser treatment
Study NCT02398422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening Project Protocol
Description: The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention.
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04214067 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Undergo vaginal brachytherapy
Study NCT04214067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo vaginal brachytherapy
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04214067 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT04214067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04214067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04214067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01697553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home automation pack coupled to teleassistance service
Study NCT01697553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home without automation pack coupled to teleassistance service
Study NCT01689727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Technetium Tc 99m EC20
Study NCT01756079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Study NCT01756079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN-2b
Study NCT01756079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Study NCT00351884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin AM
Study NCT00351884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin pm
Study NCT00351884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo